Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
RatOtherSprague-DawleyMaleIntravenous infusion, and oral dosing at the highest dose0.3, 1 or 3 mg/kg intravenously; also 3 mg/kg orallyAdministered before electrolytic carotid injury, with time to occlusion monitor…
Model: Electrolytic injury of the carotid artery in anaesthetised rats, producing thrombotic vessel occlusion
Rivaroxaban at 1 and 3 mg/kg prevented occlusion in all vessels across the 30 min observation window (median occlusion time greater than 30 min), exceeding enoxaparin 10 mg/kg (median 21.6 min), while 0.3 mg/kg did not prolong occlusion time versus vehicle. Oral dosing at 3 mg/kg was also effective…
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.